P
The startup develops a cancer diagnosis technology that detects drug resistance signals by monitoring the activation of cancer signal pathways through direct observation of relevant proteins. This enables healthcare providers to predict drug efficacy in real-time, improving treatment decisions for patients.
Updated 3 months ago
Funding
$19M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- The startup develops a cancer diagnosis technology that detects drug resistance signals by monitoring the activation of cancer signal pathways through direct observation of relevant proteins. This enables healthcare providers to predict drug efficacy in real-time, improving treatment decisions for patients.